Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. (NQ: PHVS )

24.90 +0.31 (+1.26%)
Streaming Delayed Price Updated: 3:34 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharvaris N.V.

< Previous 1 2 Next >
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks 
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Present at the APAAACI 2023 International Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Present at the CIIC Fall 2023 Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Present at the 18th German Allergy Congress
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces $70 Million Private Placement Financing
From Pharvaris N.V.
Via GlobeNewswire
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.